We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-20.33%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.3B
AUM Growth
-$379M
Cap. Flow
+$105M
Cap. Flow %
8.09%
Top 10 Hldgs %
48.93%
Holding
86
New
8
Increased
9
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
GRNA
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
+$60.1M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$28.4M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$22.7M
4
APLS
Apellis Pharmaceuticals
APLS
+$22.1M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$16.9M

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$26.9M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$13.1M
3
VERV
Verve Therapeutics
VERV
+$11.7M
4
CYTK icon
Cytokinetics
CYTK
+$10.7M
5
ZYME icon
Zymeworks
ZYME
+$9.83M

Sector Composition

Rank Sector Weight
1 Healthcare 98.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
51
Eledon Pharmaceuticals
ELDN
$285M
$5.14M 0.39%
1,305,095
– –
ELEV
52
DELISTED
Elevation Oncology
ELEV
$5M 0.38%
1,983,165
– –
VIGL
53
DELISTED
Vigil Neuroscience
VIGL
$4.21M 0.32%
+616,786
New +$8.14M
MRTX
54
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.11M 0.32%
50,000
-25,000
-33% -$2.56M
PLRX icon
55
Pliant Therapeutics
PLRX
$65M
$3.38M 0.26%
482,413
– –
ITOS
56
DELISTED
iTeos Therapeutics
ITOS
$3.22M 0.25%
100,000
-50,000
-33% -$1.82M
ICVX
57
DELISTED
Icosavax, Inc. Common Stock
ICVX
$3M 0.23%
426,393
– –
GLS
58
DELISTED
Gelesis Holdings, Inc.
GLS
$2.75M 0.21%
+626,108
New +$3.12M
PYXS icon
59
Pyxis Oncology
PYXS
$236M
$2.7M 0.21%
668,854
– –
HARP
60
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.69M 0.21%
54,060
– –
BCEL
61
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.54M 0.19%
800,000
+526,500
+193% +$1.28M
CABA icon
62
Cabaletta Bio
CABA
$455M
$2.34M 0.18%
1,154,424
– –
DMRA
63
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$2.25M 0.17%
40,810
– –
RCOR
64
DELISTED
Renovacor, Inc.
RCOR
$2.12M 0.16%
500,000
– –
MGTX icon
65
MeiraGTx Holdings
MGTX
$1.21B
$2.08M 0.16%
150,000
– –
ATXS
66
DELISTED
Astria Therapeutics
ATXS
$2.01M 0.15%
300,000
-252,903
-46% -$1.51M
AKUS
67
DELISTED
Akouos Inc
AKUS
$1.87M 0.14%
394,500
– –
YMAB
68
DELISTED
Y-mAbs Therapeutics
YMAB
$1.78M 0.14%
150,000
-150,000
-50% -$1.54M
GOSS icon
69
Gossamer Bio
GOSS
$87M
$1.72M 0.13%
198,382
– –
AUTL
70
Autolus Therapeutics
AUTL
$562M
$1.64M 0.13%
392,167
– –
CMMB
71
Chemomab Therapeutics
CMMB
$14.1M
$1.38M 0.11%
+72,042
New +$1.42M
ANAB icon
72
AnaptysBio
ANAB
$1.68B
$1.24M 0.1%
50,000
-50,000
-50% -$1.51M
DTIL icon
73
Precision BioSciences
DTIL
$207M
$1.07M 0.08%
11,551
– –
LENZ
74
LENZ Therapeutics
LENZ
$168M
$1.04M 0.08%
29,022
– –
IMV
75
DELISTED
IMV Inc. Common Shares
IMV
$337K 0.03%
23,437
– –
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2022 Portfolio in Review

As of Q1 2022, Cormorant Asset Management held 86 positions worth $1.3B, down 23% from $1.68B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Cormorant Asset Management deployed $105M of net new capital in Q1 2022, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was GreenLight Biosciences Holdings, PBC Common Stock: 6,710,540 shares worth $62M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Beam Therapeutics, an estimated $26.9M trimmed.

  • Cormorant Asset Management's largest Q1 2022 buy was GreenLight Biosciences Holdings, PBC Common Stock: 6,710,540 shares worth $62M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q1 2022, an estimated $28.4M increase.
  • Cormorant Asset Management's biggest Q1 2022 reduction was Beam Therapeutics, cutting an estimated $26.9M.
  • Cormorant Asset Management fully exited Aclaris Therapeutics in Q1 2022, selling an estimated $13.1M.
  • Cormorant Asset Management's ten largest holdings make up 49% of its $1.3B portfolio in Q1 2022.
  • Cormorant Asset Management opened 8 new positions and closed 9 in Q1 2022.
  • Cormorant Asset Management's portfolio value fell 23% quarter-over-quarter to $1.3B.

Based on Cormorant Asset Management's 13F filing for Q1 2022, filed 16 May 2022.